Chemours (NYSE:CC) Raised to Strong-Buy at Zacks Research

Chemours (NYSE:CC) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.39 EPS, Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

CC has been the topic of several other research reports. Alembic Global Advisors restated an “overweight” rating and set a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. UBS Group increased their price target on Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Mizuho decreased their price objective on Chemours from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Wednesday, July 1st. JPMorgan Chase & Co. boosted their price objective on Chemours from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada raised their target price on shares of Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Chemours presently has an average rating of “Moderate Buy” and a consensus price target of $24.10.

Chemours Stock Performance

NYSE:CC opened at $18.24 on Tuesday. The company has a fifty day simple moving average of $20.61 and a two-hundred day simple moving average of $19.85. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -6.91 and a beta of 1.41. The company has a quick ratio of 0.87, a current ratio of 1.82 and a debt-to-equity ratio of 18.98. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. The business had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a positive return on equity of 52.49% and a negative net margin of 6.82%.The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 earnings per share. As a group, equities analysts anticipate that Chemours will post 1.18 earnings per share for the current fiscal year.

Institutional Trading of Chemours

Institutional investors have recently bought and sold shares of the business. Atlas Capital Advisors Inc. acquired a new stake in shares of Chemours during the 4th quarter worth about $26,000. Aster Capital Management DIFC Ltd acquired a new position in Chemours in the fourth quarter valued at approximately $28,000. Covestor Ltd boosted its holdings in Chemours by 204.7% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after purchasing an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Chemours in the fourth quarter valued at approximately $31,000. Finally, Rothschild Investment LLC increased its stake in Chemours by 87.0% in the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 1,255 shares during the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.